The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Colon cancer is on the rise in younger people, which is why testing guidelines recommend testing starting at 45 for those at average risk. To stop colon cancer, it’s important to know when and how to ...

Time for a rear-ality check. Colorectal cancer rates have been rising among adults younger than 50 since the 1990s, a troubling trend that has perplexed scientists. Because of the increase in cases, ...

The American Cancer Society released updated guidelines for colorectal cancer screening, adding options for a blood-based screening test and new at-home screening kits.

An investigational blood test for early detection of colorectal cancer (CRC) in average-risk adults met the primary endpoints of sensitivity and specificity in the PREEMPT CRC study, the largest study ...

The American Cancer Society is adding some new testing options to its screening guidelines for colorectal cancers – and for the first time, that includes a blood test.Colonoscopies are still ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

UCLA research finds that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the United States Preventive Services Task Force (USPSTF) lowered the recommended ...

Researchers identified a six-gene signature in microscopic colorectal cancer (CRC) liver metastases that may help predict ...